The Laboratory Report Summer 2012

The

Summer 2012

Laboratory Report A Publication of the Department of Pathology and Genomic Medicine

Dr. Geoffrey Land Receives Celebration of Life Award

D

r. Geoffrey Land was the recipient of the Celebration of Life Award at the Methodist J.C. Walter Jr. Transplant Center’s annual Celebration of Life event in Crain Garden on April 12th. Dr. A. Osama Gaber, medical director of transplantation for the Center, presented Dr. Land with the award in recognition of his leadership in the transplant program and for being a vital member of the transplant team. ‚Geoff is essential to the success of our ever-growing Center,‛ said Dr. Gaber. ‚He and his staff in the Histocompatibility and Transplant Immunology Laboratory impart a fundamental service that allows us to provide excellent care to our patients. Transplant surgery wouldn’t

Dr. Land with the Celebration of Life Award.

CAP ‘12 THE Pathologists’ Meeting: The annual meeting of the College of American Pathologists will be held from September 9-12, 2012 at the Manchester Grand Hyatt in San Diego, California. Dr. Philip Cagle will moderate a Scientific Plenary Session and Drs. Geoffrey Land and Randall Olsen will present a short course. In addition, 14 Department trainees will present posters or abstracts. Registration is still open at cap.org/ annual_meeting/2012.

be possible without them.‛ Dr. Land is the medical director of Histocompatibility and Transplant Immunology (HLA) in the Department of Pathology and Genomic Medicine.

The HLA Laboratory provides tissue typing, cross-matching, and antibody identification testing services for transplant patients in The Methodist Hospital System and at institutions served by The Methodist Hospital System Reference Laboratory.

For more information on Dr. Land, visit methodisthealth.com/Land. For more information on the Methodist J.C. Walter Jr. Transplant Center, visit methodisthealth.com/transplantcenter. 

Table of Contents

2

Breakthroughs in Molecular Testing of Lung Cancer Drs. Abdus Saleem and Donald Weilbaecher Retire After Decades of Service

3

Department Ranks Among Best in World for Abstract Presentations New Diagnostic Test Offerings

4 5 6

In Focus: The HLA Team Lab Stats: Methodist Sugar Land Hospital Department Faculty Receive Teaching Awards New Trainees Start on July 1st

34th Conference on Pediatric Disease July 30-August 2, 2012 Viceroy Snowmass Hotel Snowmass Village, Colorado

Young Pathologists’ Section Retreat August 18-19, 2012 Hyatt Regency Hill Country San Antonio, Texas

For more information on these upcoming events for the Texas Society of Pathology, visit texpath.org.

7

Methodist Laboratory Science Students Win Bowl Competition Summer Students Start on June 4th

8

Trainee Spotlight

The

LABORATORY REPORT

2

Breakthroughs in Molecular Testing of Lung Cancer

L

ung cancer remains the leading cause of cancer deaths worldwide, but recent advances in diagnosis and treatment will likely improve these traditionally grim statistics.

Genomic data and radiological studies continue to contribute novel information on disease histology and pathogenesis, allowing for the development and validation of new, targeted molecular therapies and the establishment of clearer correlations between specific types of lung cancer and responses to specific therapies. ‚Genomic sequencing provides us with molecular biomarkers, usually oncogene mutations, that can have significant predictive value,‛ said Dr. Philip Cagle, medical director of pulmonary pathology for the Department. ‚Identifying these markers in patient samples allows pathologists to advise treating physicians on the selection of therapies that are

more ‘personalized’ to specific targets in the patients’ lung cancer.‛ Two predictive biomarkers for nonsmall-cell lung cancer (epidermal growth factor receptor [EGFR] and anaplastic lymphoma kinase [ALK]) have been clinically validated, and tests for them are now available at Methodist. Approximately 12 other biomarkers are in various stages of investigation.

Dr. Cagle will moderate a scientific plenary session on molecular testing of lung cancer at the annual meeting of the College of American Pathologists on September 9th in San Diego. The new testing guidelines for predictive biomarkers in lung cancer are expected to be unveiled at that meeting. These guidelines are

Spectra from an EGFR test.

established through a special committee of the College of American Pathologists, the Association for Molecular Pathology, and the International Association for the Study of Lung Cancer.

For more information on molecular testing of lung cancer at Methodist, please contact Dr. Randall Olsen in the Molecular Diagnostics Laboratory at rjolsen@tmhs.org. For more information on Dr. Philip Cagle, visit methodisthealth.com/ Cagle. 

Drs. Abdus Saleem and Donald Weilbaecher Retire After Decades of Service

D

r. Abdus The Department has estabSaleem, colished the Dr. Abdus Saleem director of the Award. The award will be Coagulation Laboratory given annually to a member and associate medical of the Department who director of hematopatholmost epitomizes Dr. ogy for the Department, Saleem’s outstanding proand Dr. Donald Weilfessionalism and commitbaecher, medical director ment to diversity. of autopsy pathology for Dr. Weilbaecher joined the the Department, have medical staff at Methodist in retired after a combined 1981.

From left, Drs. Ethan Natelson, Abdus Saleem, James Musser, and James Davis 67 years of dedicated ‚During this time, he has nd at a retirement reception on June 22 . service to The Methodist Hosserved as Director, Autopsy pital System.

Service, and has generously shared his Dr. Saleem joined the medical staff at ‚Abdus is the embodiment of collegialexpertise with residents, medical stuMethodist in July of 1976 when he was ity, and it has been an honor to work with dents, and other trainees,‛ said Dr. recruited from the Pennsylvania State him,‛ said Dr. James Musser, chair of the Musser. Dr. Weilbaecher also has been University College of Medicine in HerDepartment. ‚He is a tremendous physithe Department’s leader in cardiovascushey. He has trained numerous local cian and has been an important mentor in lar pathology for much of his career.  hematopathologists over the years, inour training programs. He will be missed, cluding Drs. Jacqueline O’Hare, Munir but we wish him well in this next chapter Shahjahan, Choladda Curry, Randall of his life.‛ Olsen, Thu Ngo, and Christine Finch.

The

LABORATORY REPORT

3

Department Ranks Among Best in World for Abstract Presentations

T

he Methodist Department of Pathology and Genomic Medicine is in the top 20 of all institutions worldwide for first-authored scientific abstracts accepted for presentation at the annual meeting of the United States & Canadian Academy of Pathology (USCAP). The Department also ranked in the top 5% of all medical institutions. ‚Our faculty and trainees are very active academically,‛ said Dr. Alberto Ayala, deputy chief of pathology for the Department. ‚We expect to rank even higher next year.‛

The ranking information was relayed to Department leadership in June in a letter from Dr. Bruce Smoller, Executive Vice-President and Secretary-Treasurer of USCAP. In 2012, there were over 3,000 scientific abstracts submitted to USCAP from more than 400 medical school programs and academic institutions (over 200 in the U.S. and Canada, and 200 from the rest of the world).

For more information on the United States & Canadian Academy of Pathology, visit uscap.org. 

Hundreds Attend Houston Lung Symposium

M

ore than 250 physicians and scientists attended the Houston Lung Symposium on April 28th and 29th in The Methodist Hospital Research Institute auditorium. The event was a collaboration between the Houston Society of Clinical Pathologists and the Methodist Department of Pathology and Genomic Medicine. The two-day symposium featured renowned speakers from around the world.

New Diagnostic Test Offerings: Lung Cancer and Glial Tumor Mutation Panels The Molecular Diagnostics Laboratory of The Methodist Hospital System has developed new gene mutation panels for lung and brain cancer. Somatic mutation profiling determines whether patients with non-small cell lung cancer or glial brain tumors could benefit from a targeted therapy. Non-small cell lung cancer accounts for approximately 85-90% of lung cancers, and includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Glial tumors are the most common form of central nervous system neoplasm, and include astrocytomas, ependymomas, oligodendrogliomas, and glioblastoma multiforme.

The new lung cancer panel tests for mutations in the genes encoding epidermal growth factor receptor

(EGFR) and V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS).

The new glial tumor panel genotypes the isocitrate dehydrogenase 1 (IDH1) and IDH2 genes. IDH1 and IDH2 gene mutations have also recently been associated with acute myeloid leukemia, myelodysplastic syndrome, and prostate cancer.

These assays are performed on the Sequenom MassARRAY analyzer that determines DNA sequences using PCR and MALDI-TOF mass spectrometry. EGFR, IDH1 and IDH2 testing was previously performed at a reference laboratory, and KRAS testing was previously performed using pyrosequencing. Validation studies for both panels were supported, in part, through departmental microgrants. The new molecular diagnostic panels will be introduced inhouse in August.

H&E stain of glioblastoma multiforme.

For more information on these panels or other tests offered by the Molecular Diagnostics Laboratory, please contact Dr. Randall Olsen at 713-441-6802 or Ms. Heather Hendrickson at 713-441-0504. 

The

LABORATORY REPORT

4

In Focus: The HLA Team

T

he Histocompatibility and Transplant Immunology Laboratory provides tissue typing, crossmatching, and antibody identification testing services for solid organ and bone marrow transplant patients in The Methodist Hospital System and at institutions served by The Methodist Hospital System Reference Laboratory.

The HLA laboratory also performs microsatellite analysis for engraftment monitoring, assays for immune cell function monitoring, and human leukocyte antigen (HLA) typing for disease associations and pharmacogenomics.

The Department of Pathology and Genomic Medicine has a team of three fulltime faculty that continues to grow to keep pace with the J.C. Walter Jr. Transplant Center at Methodist that it serves, now the largest transplant center in Texas and the Southwest.

Geoffrey A. Land, Ph.D., D(ABB) Medical Director, Histocompatibility and Transplant Immunology Dr. Land received his Ph.D. in microbiology from the Tulane University Medical Center in New Orleans, Louisiana. He then completed an NIH-sponsored research fellowship in microbiology at the Duke University Medical Center in Durham, North Carolina.

Dr. Land has been in the fields of histocompatibility and immunogenetics for over 30 years, and has been actively involved in quality assurance and the standardization of histocompatibility laboratory procedures and practices. He remains an active laboratory inspector for the College of American Pathologists and the American Society for Histocompatibility and Immunogenetics (ASHI). He is the immediate past-president of ASHI and is the president-elect of the Texas Transplantation Society.

For more information on Dr. Land, visit methodisthealth.com/Land.

Kevin Burns, M.D. Co-Medical Director, Histocompatibility and Transplant Immunology Dr. Burns received his M.D. degree in 2006 from The University of Texas Health Science Center at San Antonio. He completed his clinical pathology residency in 2009, his transfusion medicine/blood banking fellowship in 2010, and his HLA fellowship in June of this year, all here at Methodist. Dr. Burns joined the Department as faculty in July of this year and became co-director of the Histocompatibility and Transplant Immunology Laboratory.

Dr. Burns is board certified in both clinical pathology and blood banking/ transfusion medicine.

For more information on Dr. Burns, visit methodisthealth.com/Burns.

Dr. Burns in the laboratory with HLA Medical Technologist Andreea Acevedo.

The HLA team: from left, Drs. Geoffrey Land, Kevin Burns, and Smaroula Dilioglou.

Smaroula Dilioglou, Ph.D., D(ABHI) Associate Medical Director, Histocompatibility and Transplant Immunology Dr. Dilioglou received her Ph.D. in immunology from the University of Mississippi Medical Center in Jackson, Mississippi. She then completed her postdoctoral training at the St. Jude’s Children’s Research Hospital in Memphis, Tennessee. In addition to providing clinical services, Dr. Dilioglou is especially involved in HLA education of residents and fellows.

For more information on Dr. Dilioglou, visit methodisthealth.com/Dilioglou.

For more information on the Histocompatibility and Transplant Immunology Laboratory at Methodist, please contact Dr. Geoffrey Land at gland@tmhs.org. 

Dr. Dilioglou mentoring trainee Dr. Susan Haley in the Flow Cytometry Laboratory.

The

LABORATORY REPORT

5

Lab Stats: Methodist Sugar Land Hospital Medical Director: Seema Mullick, M.D. Dr. Mullick received her medical degree from the Christian Medical College in Ludhiana, India. She completed a pathology residency program and a cytopathology fellowship at the Baylor College of Medicine in Houston, Texas, followed by a surgical pathology fellowship at The University of Texas M.D. Anderson Cancer Center.

Faculty: Bisong Haupt, M.D. Dr. Haupt received her M.D. degree from the Southeast University School of Medicine in Nanjing, China. She is a graduate of the pathology training programs at Methodist, and a general surgical pathologist.

Ognjen Kosarac, M.D. Dr. Kosarac received his medical degree from the University of Sarajevo in Bosnia and Herzegovina. Like Dr. Haupt, he is also a graduate of the pathology training programs at Methodist. He has subspecialty certification in cytopathology.

Director: Donna Hermis, M.H.A. Ms. Hermis received her Master of Healthcare Administration from Texas Woman’s University. In addition to being the director of the laboratory at Methodist Sugar Land Hospital, she is also the hospital safety officer.

Manager: Rosalie Thornblom Ms. Thornblom received her Bachelor of Science in Medical Technology from the University of Mary Hardin-Baylor.

She has been with the Sugar Land laboratory since 2004, and became the manager in 2007.

Staff: The laboratory currently employs 42 staff members that include shift coordinators, technologists, histologists, processors, and technicians. These employees demonstrate their ICARE values every day to ensure that the laboratory is efficient and that the patients and medical staff at Methodist Sugar Land Hospital are well served by their efforts. 

“We have an incredible group here in the Sugar Land laboratory. We all really love what we do, and we love Fort Bend County; it’s a great place to work and serve our patients.”

Seema Mullick, M.D.

“Dr. Mullick is a remarkable medical director. I have enjoyed working with her and the rest of the faculty and staff here.”

Bisong Haupt, M.D.

“I was pleased to be able to remain at Methodist after my training; it is an impressive hospital system, and I enjoy working at both the main hospital in the Texas Medical Center and at Sugar Land.”

Ognjen Kosarac, M.D.

“This is a busy laboratory, especially with the recent growth at the hospital and the expansion of the Breast Center. We all work together to make accuracy and safety our main priorities, and we do it well.”

Donna Hermis, M.H.A.

“Getting tests completed right and quickly is very important. It takes a good team to do that, and that’s what we have here.”

Jennifer Selvidge, MLT Specialist

“Our laboratory continues to evolve and expand. Like the hospital and the community it serves, it just keeps getting better.”

Rosalie Thornblom

Pictures from top: Dr. Mullick at the microscope; Dr. Haupt at the chemistry analyzer; Dr. Kosarac in the Histology Laboratory; Ms. Hermis in her office; and Ms. Thornblom (right) with MLT Specialist Jennifer Selvidge.

The

LABORATORY REPORT

6

Department Faculty Receive Teaching Award

T

wo faculty members in the Department received teaching awards from the Graduate Medical Education (GME) Department. Dr. Jae Ro, medical director of surgical pathology, and Dr. Arthur Zieske, co-director of hematopathology, received the GME Faculty Teaching Award on July 2nd, from Dr. Judy Paukert, the GME Designated Institutional Official for The Methodist Hospital. ‚The success of our many programs relies heavily on the contributions of

great teachers and mentors like Dr. Ro and Dr. Zieske,‛ said Dr. Paukert. ‚We truly appreciate their efforts with our trainees.‛ The awards are given annually for exemplary teaching and are voted on by the residents in their respective programs.

For more information on Department training programs, visit methodisthealth.com/ pathologytraining. 

Jae Ro, M.D., Ph.D.

Arthur Zieske, M.D.

New Trainees Start on July 1st

T

he Department welcomed 4 new residents and 12 new fellows on July 2nd during a half-day trainee orientation session led by Dr. Suzanne Powell, vice-chair of education for the Department. The session followed a fourday orientation provided by the hospital’s GME office. Dr. Powell and the education manager and coordinators greeted the incoming trainees and apprised them of the various support services in the Department, including the training program coordinators, a poster printing service, and the Office of Academic Development. ‚Our department is large and busy; we service a multi-site hospital system as well as our reference laboratory clients.

We want to make sure our new trainees transition into their programs quickly and relatively seamlessly,‛ said Dr. Powell. ‚We are preparing the next generation of practicing pathologists and investigative pathologists, and we want to ensure they have an outstanding training experience.‛ The Department currently has 40 existing trainees, with 21 of them having completed their residency or fellowship program and graduated as of June 30th. With the 16 new trainees, the Department will have a total of 38 residents and fellows for the academic year 2012-13. The Department of Pathology and Genomic Medicine has a residency program, a resident research program, and 11 fellowship programs – the most training programs of any department at Methodist.

PGY1 Residents Miguelina De la Garza, M.D. Escuela de Medicina Ignacio A. Santos, Monterrey, Mexico

Molecular Genetic Pathology Elizabeth McQuitty, M.D. AP/CP Residency The Methodist Hospital

Maren Y. Fuller, M.D. The University of Texas Medical School, Houston

Neuropathology Jo Elle Peterson, M.D. AP/CP Residency The Methodist Hospital

Jordan A. Roberts, M.D. Louisiana State University School of Medicine, New Orleans Eric Salazar, M.D., Ph.D. Weill Cornell Medical College, New York Incoming Fellows Blood Bank/Transfusion Medicine Miho Teruya, M.D. Internal Medicine Baylor College of Medicine Cytopathology Lindsay Waters, M.D. AP/CP Residency The Methodist Hospital Bryan Janssen, M.D. AP/CP Residency The Methodist Hospital Hematopathology Adeel Muhammad Raza, M.D. AP/CP Residency St. John Hospital and Medical Center, Detroit Ramesh Bhagat, M.D. AP/CP Residency The University of Texas Southwestern Medical Center, Dallas

Surgical Pathology Laura Kidd, M.D. AP/CP Residency The University of Texas Medical School, Houston Crystal Trujillo, M.D. AP/CP Residency The University of Texas Medical School, Houston Sadhna Dhingra, M.D. AP/CP Residency The University of Texas Medical School, Houston Cecilia Clement, M.D. AP/CP Residency The University of Texas Medical Branch, Galveston Andrea Haws, M.D. AP/CP Residency Baylor College of Medicine For more information on Department training programs, visit methodisthealth.com/pathologytraining. 

The

LABORATORY REPORT

7

Methodist Laboratory Science Students Win Bowl Competition

T

he team of four students currently enrolled in The Methodist Hospital Medical Laboratory Science (MLS) Program won first place at the Texas Association for Clinical Laboratory Science (TACLS) Student Bowl competition on March 29th as part of the TACLS Annual Meeting in Fort Worth, Texas. A Methodist team has won the competition 12 times in the past 24 years. ‚Winning the TACLS Bowl is testament to the strength of our program,‛ said Tatia Feltman, program director for the Methodist MLS Program. ‚We are always proud of our students, and especially so for taking first prize at a state-

Laboratory Sciences (NAACLS). Upon successful completion of the program, students will qualify for the examination and certification by the Board of Certification of the American Society of Clinical Pathology (ASCP).

Many of the graduates of the program go on to work at Methodist in one of our many pathology laboratories. The Methodist MLS Program has Methodist MLS Program students from left: Xinh Nguyen, Bianca Natividad, Margaret Renfro, and Morgan Kilty. been in existence since 1947.

For more information on the Methodist MLS Program, visit methodwide competition such as this.‛ isthealth.com/mlsprogram.  The Methodist MLS Program is a twelve-month professional course of study that is fully accredited by the National Accrediting Agency for Clinical

Summer Students Start on June 4th

T

welve summer students recently began their three-month program in the laboratories of some of the Department’s faculty. ‚We have several impressive research programs in our Department,‛ said Dr. Patricia Chevez-Barrios, founder and director of the Research Institute Summer Student Program and director of the Ocular Pathology Research Laboratory. ‚Our faculty are particularly committed to developing the next generation of physician scientists, and the Summer Student Program is a great opportunity to do that.‛ First established in 2005, the Summer Student Program matches students with faculty mentors in Research Institute laboratories from June to August (10 weeks) and centers on a single research project. During this time, the students also attend required weekly didactic lectures given by the mentors and invited speakers. Students present their work at the end of the program at a student retreat.

Center for Molecular and Translational Human Infectious Diseases Research Laboratory of Dr. Edward Graviss Valerie Brooker – Texas Tech

Dr. Paul Sumby (right) with Summer Student Michael Au.

Laboratory of Dr. Wesley Long Alan Hsieh, Rice University Laboratory of Dr. James M. Musser Meredith Harrell – Paul Foster School of Medicine Gabriela Hinojosa-Garza – Tecnolόgico de Monterrey Oanh Truong – Rice University Erika Versalovic – Colorado College Laboratory of Dr. Randall Olsen Deborah Saddington – Southwestern University Laboratory of Dr. Paul Sumby Michael Au – Southwestern University

Ocular Pathology Laboratory Director, Dr. Patricia Chevez-Barrios Maria Ethel Aguirre-Flores – Tecnolόgico de Monterrey Aravindh Ganapathy – Texas A&M University Cancer Pathology Laboratory Director, Dr. Youli Zu Eduardo Camacho-Martinez – Tecnolόgico de Monterrey Lucia Wang – Washington University, St. Louis For more information on the Research Institute Summer Student Program, visit methodisthealth.com/ SummerStudentProgram.

The

LABORATORY REPORT

8

Trainee Spotlight: Byron Moore, M.D. Surgical Pathology Fellow

D

r. Byron Moore, a surgical pathology fellow, is the recipient of the Graduate Medical Education (GME) Resident Leadership Award for the 2011-2012 academic year.

Dr. Moore received the award specifically for his exemplary leadership and service to GRE. This is a special award bestowed annually upon residents, as determined by the GME Designated Institutional Official, who have shown great leadership and commitment with their participation in extracurricular responsibilities in GME. Dr. Moore received his medical degree from The University of Texas Southwestern Medical School in Dallas and completed all of his postdoctoral training at Methodist, which included an AP/CP residency and fellowships in blood banking/transfusion medicine and surgical pathology.

Dr. Moore (right) receiving his award from Dr. Judy Paukert, GME Designated Institutional Official for The Methodist Hospital.

RECENT PUBLICATIONS Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. Characterization of Polymyxin B-induced Nephrotoxicity: Implications for Dosing Regimen Design. Antimicrob Agents Chemother. 2012 Jun 11. [Epub ahead of print] Avecilla ST, Ferrell C, Chandler WL, Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol. 2012 Apr;137(4):572-4.

Bae YS, Ro JY, Shim HS, Hong SW, Yoon SO. Pulmonary sclerosing haemangioma with metastatic spread to stomach. Histopathology.

2012 Jun;60(7):1162-4.

Cagle PT, Chirieac LR. Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med. 2012 May;136(5):504-9.

Crombet O, Lastrapes K, Zieske A, Morales-Arias J. Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with T-cell acute lymphoblastic leukemia and ABL1 amplification. Pediatr Blood Cancer. 2012 Aug;59(2):333-4.

Devos JM, Gaber AO, Knight RJ, Land GA, Suki WN, Gaber LW, Patel SJ. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int. 2012 May 23. [Epub ahead of print] Fittipaldi N, Olsen RJ, Beres SB, Van Beneden C, Musser JM. Genomic analysis of emm59 group A Streptococcus invasive strains, United States. Emerg Infect Dis. 2012 Apr;18(4):650-2.

Geyer FC, Lacroix-Triki M, Colombo PE, Patani N, Gauthier A, Natrajan R, Lambros MB, Khalifeh I, Albarracin C, Orru S, Marchiò C, Sapino A, Mackay A, Weigelt B, Schmitt FC, Wesseling J, Sneige N, Reis-Filho JS. Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. Histopathology. 2012 May;60(6B):E115-30.

Gorman BK, Kosarac O, Chakraborty S, Schwartz MR, Mody DR. Comparison of breast carcinoma prognostic/predictive biomarkers on cell blocks obtained by various methods: cellient, formalin and thrombin. Acta Cytol. 2012;56(3):289-96.

Grilley-Olson JE, Hayes DN, Moore DT, Leslie KO, Wilkerson MD, Qaqish BF, Hayward MC, Cabanski CR, Yin X, Socinski MA, Stinchcombe TE, Thorne LB, Allen TC, Banks PM, Beasley MB, Borczuk AC, Cagle PT, Christensen R, Colby TV, Deblois GG, Elmberger G, Graziano P, Hart CF, Jones KD, Maia DM, Miller CR, Nance KV, Travis WD, Funkhouser WK. Validation of Interobserver Agreement in Lung Cancer Assessment Hematoxylin-Eosin Diagnostic Reproducibility for Non-Small Cell Lung Cancer-The 2004 World Health Organization Classification and Therapeutically Relevant Subsets. Arch Pathol Lab Med. 2012 May 14. [Epub ahead of print] Hu Y, Zhao Q, Graviss EA, Jiang W, Yuan Z, Xu B. Use of the T-SPOT.TB assay to screen latent tuberculosis infection among the TB contacts in Shanghai, China. J Infect. 2012 Jul;65(1):39-48.

Jian PY, Godoy G, Coburn M, Lynch G, Ro JY, Zhai QJ, Nishino M, Lerner SP. Adenocarcinoma following urinary diversion. Can Urol Assoc J. 2012 Apr;6(2):E77-80.

Continued page 9

The

LABORATORY REPORT

9

RECENT PUBLICATIONS continued Ko K, Ro JY, Hong EK, Lee S. Micropapillary lung cancer with breast metastasis simulating primary breast cancer due to architectural distortion on images. Korean J Radiol. 2012 Mar;13(2):249-53.

Kundu UR, Guo M, Landon G, Wu Y, Sneige N, Gong Y. Fine-needle aspiration cytology of sclerosing adenosis of the breast: a retrospective review of cytologic features in conjunction with corresponding histologic features and radiologic findings. Am J Clin Pathol.

2012 Jul;138(1):96-102.

Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Panageas KS. Response to Weltman and Fleury Malheiros, re Lassman et al. Neuro Oncol. 2012 Jun;14(6):677-678.

Lee H, Jung SY, Ro JY, Kwon Y, Sohn JH, Park IH, Lee KS, Lee S, Kim SW, Kang HS, Ko KL, Ro J. Metaplastic breast cancer: clinicopathological features and its prognosis. J Clin Pathol. 2012 May;65(5):441-6.

Lee SY, Kim KR, Park JY, Ro JY. Wilms' Tumor with Long-delayed Recurrence: 25 Years after Initial Treatment. Korean J Urol. 2012 Apr;53(4):288-92.

Marconescu P, Graviss EA, Musher DM. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin. Scand J Infect Dis. 2012 Jun 5. [Epub ahead of print] McGowan P, Nelles N, Wimmer J, Williams D, Wen J, Li M, Ewton A, Curry C, Zu Y, Sheehan A, Chang CC. Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system. Am J Clin Pathol. 2012 Apr;137(4):665-70.

McQuitty E, Ro JY, Truong LD, Shen SS, Zhai Q, Ayala AG. Lymphovascular invasion in micropapillary urothelial carcinoma: a study of 22 cases. Arch Pathol Lab Med. 2012 Jun;136(6):635-9.

Ozcan A, Truong LD. PAX2 and PAX8 Expression in the Ovarian Surface Epithelium and Inclusion Cysts. Am J Surg Pathol. 2012 Mar 31. [Epub ahead of print] Shen SS, Truong LD, Scarpelli M, Lopez-Beltran A. Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful? Arch Pathol Lab Med. 2012 Apr;136(4):410-7.

Shinder R, Ramirez SA, Chévez-Barrios P, Gombos DS. Re: "retinoblastoma associated orbital cellulitis". Ophthal Plast Reconstr Surg.

2012 May;28(3):235-7.

Shu I, Devaraj S, Hanson SE, Little RR, Wang P. Comparison of hemoglobin A1c measurements of samples with elevated fetal hemoglobin by three commercial assays. Clin Chim Acta. 2012 May 26. [Epub ahead of print] Wadhwa L, Bond WS, Perlaky L, Overbeek PA, Hurwitz MY, Chévez-Barrios P, Hurwitz RL. Embryonic Retinal Tumors in SV40 TAg Transgenic Mice Contain CD133+ Tumor-Initiating Cells. Invest Ophthalmol Vis Sci. 2012 Jun 8;53(7):3454-62.

Wimmer JL, Long SW, Cernoch P, Land GA, Davis JR, Musser JM, Olsen RJ. A Strategy for Rapid Identification and Antibiotic Susceptibility Testing of Gram-Negative Bacteria Directly Recovered from Positive Blood Cultures using the Bruker MALDI Biotyper and BD Phoenix. J Clin Microbiol. 2012 Apr 18. [Epub ahead of print] Yaziji H, Eisen R, Wick M, Swanson P, Badve S, Cartun R, Haas T, Marolt M, Hicks D, Martin A, Barry T, Alsabeh R, Taylor J, Fulton R, Goldsmith J, Shen S, Taylor C. Immunohistochemistry Cocktails Are Here to Stay: Center of Medicare and Medicaid Services Should Revise Its New Reimbursement Policy. Appl Immunohistochem Mol Morphol. 2012 Jul;20(4):331-333.

Zhou H, Schwartz MR, Coffey D, Smith D, Mody DR, Ge Y. Should LSIL-H be a distinct cytology category?: A study on the frequency and distribution of 40 human papillomavirus genotypes in 808 women. Cancer Cytopathol. 2012 May 30. [Epub ahead of print] 

The Laboratory Report The Laboratory Report is a publication of The Methodist Hospital System Department of Pathology and Genomic Medicine.

Editor-in-Chief April A. Ewton, M.D.

Claudia P. Molina, M.D. Seema Mullick, M.D. Editorial Committee Thu Ngo, M.D. Hazel L. Awalt, M.D. Steven Shen, M.D., Ph.D. Christopher Leveque, M.D. Paul Sumby, Ph.D.

Ping Wang, Ph.D. Editorial Coordinator Philip Randall

The Methodist Hospital Clare Rose, M.B.A. Manuel Hinojosa, M.H.A.

Department Chair James M. Musser, M.D., Ph.D.